Cargando…

Zelquistinel Is an Orally Bioavailable Novel NMDA Receptor Allosteric Modulator That Exhibits Rapid and Sustained Antidepressant-Like Effects

BACKGROUND: The role of glutamatergic receptors in major depressive disorder continues to be of great interest for therapeutic development. Recent studies suggest that both negative and positive modulation of N-methyl-D-aspartate receptors (NMDAR) can produce rapid antidepressant effects. Here we re...

Descripción completa

Detalles Bibliográficos
Autores principales: Burgdorf, Jeffrey S, Zhang, Xiao-Lei, Stanton, Patric K, Moskal, Joseph R, Donello, John E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743962/
https://www.ncbi.nlm.nih.gov/pubmed/35882204
http://dx.doi.org/10.1093/ijnp/pyac043
_version_ 1784848816647700480
author Burgdorf, Jeffrey S
Zhang, Xiao-Lei
Stanton, Patric K
Moskal, Joseph R
Donello, John E
author_facet Burgdorf, Jeffrey S
Zhang, Xiao-Lei
Stanton, Patric K
Moskal, Joseph R
Donello, John E
author_sort Burgdorf, Jeffrey S
collection PubMed
description BACKGROUND: The role of glutamatergic receptors in major depressive disorder continues to be of great interest for therapeutic development. Recent studies suggest that both negative and positive modulation of N-methyl-D-aspartate receptors (NMDAR) can produce rapid antidepressant effects. Here we report that zelquistinel, a novel NMDAR allosteric modulator, exhibits high oral bioavailability and dose-proportional exposures in plasma and the central nervous system and produces rapid and sustained antidepressant-like effects in rodents by enhancing activity-dependent, long-term synaptic plasticity. METHODS: NMDAR-mediated functional activity was measured in cultured rat brain cortical neurons (calcium imaging), hNR2A or B subtype-expressing HEK cells, and synaptic plasticity in rat hippocampal and medial prefrontal cortex slices in vitro. Pharmacokinetics were evaluated in rats following oral administration. Antidepressant-like effects were assessed in the rat forced swim test and the chronic social deficit mouse model. Target engagement and the safety/tolerability profile was assessed using phencyclidine-induced hyperlocomotion and rotarod rodent models. RESULTS: Following a single oral dose, zelquistinel (0.1–100 µg/kg) produced rapid and sustained antidepressant-like effects in the rodent depression models. Brain/ cerebrospinal fluid concentrations associated with zelquistinel antidepressant-like activity also increased NMDAR function and rapidly and persistently enhanced activity-dependent synaptic plasticity (long-term potentiation), suggesting that zelquistinel produces antidepressant-like effects by enhancing NMDAR function and synaptic plasticity. Furthermore, Zelquistinel inhibited phencyclidine (an NMDAR antagonist)-induced hyperlocomotion and did not impact rotarod performance. CONCLUSIONS: Zelquistinel produces rapid and sustained antidepressant effects by positively modulating the NMDARs, thereby enhancing long-term potentiation of synaptic transmission.
format Online
Article
Text
id pubmed-9743962
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97439622022-12-13 Zelquistinel Is an Orally Bioavailable Novel NMDA Receptor Allosteric Modulator That Exhibits Rapid and Sustained Antidepressant-Like Effects Burgdorf, Jeffrey S Zhang, Xiao-Lei Stanton, Patric K Moskal, Joseph R Donello, John E Int J Neuropsychopharmacol Regular Research Articles BACKGROUND: The role of glutamatergic receptors in major depressive disorder continues to be of great interest for therapeutic development. Recent studies suggest that both negative and positive modulation of N-methyl-D-aspartate receptors (NMDAR) can produce rapid antidepressant effects. Here we report that zelquistinel, a novel NMDAR allosteric modulator, exhibits high oral bioavailability and dose-proportional exposures in plasma and the central nervous system and produces rapid and sustained antidepressant-like effects in rodents by enhancing activity-dependent, long-term synaptic plasticity. METHODS: NMDAR-mediated functional activity was measured in cultured rat brain cortical neurons (calcium imaging), hNR2A or B subtype-expressing HEK cells, and synaptic plasticity in rat hippocampal and medial prefrontal cortex slices in vitro. Pharmacokinetics were evaluated in rats following oral administration. Antidepressant-like effects were assessed in the rat forced swim test and the chronic social deficit mouse model. Target engagement and the safety/tolerability profile was assessed using phencyclidine-induced hyperlocomotion and rotarod rodent models. RESULTS: Following a single oral dose, zelquistinel (0.1–100 µg/kg) produced rapid and sustained antidepressant-like effects in the rodent depression models. Brain/ cerebrospinal fluid concentrations associated with zelquistinel antidepressant-like activity also increased NMDAR function and rapidly and persistently enhanced activity-dependent synaptic plasticity (long-term potentiation), suggesting that zelquistinel produces antidepressant-like effects by enhancing NMDAR function and synaptic plasticity. Furthermore, Zelquistinel inhibited phencyclidine (an NMDAR antagonist)-induced hyperlocomotion and did not impact rotarod performance. CONCLUSIONS: Zelquistinel produces rapid and sustained antidepressant effects by positively modulating the NMDARs, thereby enhancing long-term potentiation of synaptic transmission. Oxford University Press 2022-07-26 /pmc/articles/PMC9743962/ /pubmed/35882204 http://dx.doi.org/10.1093/ijnp/pyac043 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of CINP. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Regular Research Articles
Burgdorf, Jeffrey S
Zhang, Xiao-Lei
Stanton, Patric K
Moskal, Joseph R
Donello, John E
Zelquistinel Is an Orally Bioavailable Novel NMDA Receptor Allosteric Modulator That Exhibits Rapid and Sustained Antidepressant-Like Effects
title Zelquistinel Is an Orally Bioavailable Novel NMDA Receptor Allosteric Modulator That Exhibits Rapid and Sustained Antidepressant-Like Effects
title_full Zelquistinel Is an Orally Bioavailable Novel NMDA Receptor Allosteric Modulator That Exhibits Rapid and Sustained Antidepressant-Like Effects
title_fullStr Zelquistinel Is an Orally Bioavailable Novel NMDA Receptor Allosteric Modulator That Exhibits Rapid and Sustained Antidepressant-Like Effects
title_full_unstemmed Zelquistinel Is an Orally Bioavailable Novel NMDA Receptor Allosteric Modulator That Exhibits Rapid and Sustained Antidepressant-Like Effects
title_short Zelquistinel Is an Orally Bioavailable Novel NMDA Receptor Allosteric Modulator That Exhibits Rapid and Sustained Antidepressant-Like Effects
title_sort zelquistinel is an orally bioavailable novel nmda receptor allosteric modulator that exhibits rapid and sustained antidepressant-like effects
topic Regular Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743962/
https://www.ncbi.nlm.nih.gov/pubmed/35882204
http://dx.doi.org/10.1093/ijnp/pyac043
work_keys_str_mv AT burgdorfjeffreys zelquistinelisanorallybioavailablenovelnmdareceptorallostericmodulatorthatexhibitsrapidandsustainedantidepressantlikeeffects
AT zhangxiaolei zelquistinelisanorallybioavailablenovelnmdareceptorallostericmodulatorthatexhibitsrapidandsustainedantidepressantlikeeffects
AT stantonpatrick zelquistinelisanorallybioavailablenovelnmdareceptorallostericmodulatorthatexhibitsrapidandsustainedantidepressantlikeeffects
AT moskaljosephr zelquistinelisanorallybioavailablenovelnmdareceptorallostericmodulatorthatexhibitsrapidandsustainedantidepressantlikeeffects
AT donellojohne zelquistinelisanorallybioavailablenovelnmdareceptorallostericmodulatorthatexhibitsrapidandsustainedantidepressantlikeeffects